Noxopharm Ltd's (ASX:NOX) shares have entered pre-open following the ASX granting the company a trading halt, pending the public release tomorrow of clinical trial data from the first-in-human NOX66 clinical study in Georgia.
The company has a primary focus on the development of drugs to address the problem of chemotherapy and radiation-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients.
NOX66 is the first pipeline product, with later generation drug candidates under development.
The halt will remain in place until the opening of trade on Tuesday 21st November 2017, or earlier if an announcement is made to the market.